ACADIA Pharmaceuticals Inc.
ACAD
Updated: 24/09/2026, 05:43:34
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
No summaries found.
- Share price
- $25.43
- Market cap
- $4.35B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Catherine E. Owen Adams
- Employees
- 797
- IPO date
- 27/05/2004
- Beta
- 0.857
- Last dividend
- $0.00
- Day range
- $24.93 – $26.51
- 52-week range
- $19.69 – $30.96
- 1-day performance
- -3.71%
- 1-year performance
- 29.15%
- Current drawdown (1Y)
- -17.86%
- CIK
- 0001070494
- CUSIP
- 004225108
- ISIN
- US0042251084
- Created
- 07/12/2025, 01:53:53
- Last update
- 24/09/2026, 05:43:34
Track ACADIA Pharmaceuticals Inc. with an AI analyst
See which prediction-market events move ACAD, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
ACADIA Pharmaceuticals Spotlights Alzheimer's Psychosis Pipeline, NUPLAZID and DAYBUE Growth
MarketBeat • STOCK • 19/05/2026, 12:15:48
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 13/05/2026, 00:10:54
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms
MarketBeat • STOCK • 12/05/2026, 22:25:12
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
Zacks Investment Research • STOCK • 07/05/2026, 14:46:29
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 07/05/2026, 06:41:24
Acadia Pharmaceuticals (ACAD) Lags Q1 Earnings and Revenue Estimates
Zacks Investment Research • STOCK • 06/05/2026, 20:25:47
Acadia Pharmaceuticals (NASDAQ: ACAD) Earnings Preview: Key Insights and Financial Health
Market Data • Market Data • 06/05/2026, 17:00:13
Will Acadia (ACAD) Beat Estimates Again in Its Next Earnings Report?
Zacks Investment Research • STOCK • 08/04/2026, 15:10:27
Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report?
Zacks Investment Research • STOCK • 27/03/2026, 13:32:16
Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback
Proactive Investors • STOCK • 25/03/2026, 15:53:16
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised)
Zacks Investment Research • STOCK • 05/03/2026, 07:10:15
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU
Zacks Investment Research • STOCK • 04/03/2026, 10:05:46